Vialwirebiotech, curated
August 16, 2026, 2:21 PM
August 12, 2026
- 12:00 PM · BioWorld12:00 PMVogenx prices $81M IPO to advance metabolic pipeline — BioWorld
- 12:00 PM · BioWorld12:00 PMVeloxis to pay more than $46M to resolve kickback charges — BioWorld
- 11:19 AM · BioPharma Dive11:19 AMLilly files six lawsuits in bid to shut down ‘black market’ for retatrutide — BioPharma Dive
- 9:12 AM · PharmaVoice9:12 AMFormation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’ — PharmaVoice
- 9:00 AM · BioWorld9:00 AMAlmirall and Crystalo partner in dermatological drug discovery — BioWorld
- 9:00 AM · BioWorld9:00 AMXilio’s XTX-501 gains IND clearance for solid tumors — BioWorld
- 9:00 AM · BioWorld9:00 AMGilead exercises option for Macrogenics solid tumor program — BioWorld
- 9:00 AM · Labiotech (EU)9:00 AMUCB’s pipeline strategy in 2026: Doubling down on immunology and neurology — Labiotech (EU)
- 9:00 AM · BioWorld9:00 AMSuzhou Genhouse Bio discovers new DHX9 inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMNIAID contract supports Ceramedix’s gastrointestinal ARS program — BioWorld
- 9:00 AM · BioWorld9:00 AMSeries A financing at Beyang Therapeutics — BioWorld
- 8:01 AM · STAT News
- 7:40 AM · SCMP — Tech7:40 AMWill Trump’s proposed drug tariffs end India’s reign as ‘pharmacy of the world’? — SCMP — Tech
- 6:19 AM · Pharmaceutical Technology6:19 AMInvestigational CRISPR therapy succeeds in patient with drug-resistant E. Coli — Pharmaceutical Technology
- 6:04 AM · Pharmaceutical Technology6:04 AMEpicrispr, Vaderis secure pivotal study funding for rare disease assets — Pharmaceutical Technology
- 4:30 AM · STAT News
- 4:20 AM · Pharmaceutical Technology4:20 AMAlfasigma signs agreement to acquire Nordic Group — Pharmaceutical Technology
- 12:00 AM · FT — Pharmaceuticals12:00 AMHow AstraZeneca’s $400bn deal unravelled — FT — Pharmaceuticals
August 11, 2026
- 3:13 PM · SCMP — Tech3:13 PMFacebook parent Meta to unwind US$2 billion Manus AI deal after Beijing block — SCMP — Tech
- 12:12 PM · BioPharma Dive12:12 PMEx-Legend CEO takes helm at biotech startup scouring the globe for drugs — BioPharma Dive
- 12:00 PM · BioWorld12:00 PMAbcellera wows with phase II hot flash drug data — BioWorld
- 12:00 PM · BioWorld12:00 PMTransthera wins NMPA nod for post-FGFR cholangiocarcinoma — BioWorld
- 12:00 PM · BioWorld12:00 PMAlumis thesis in TYK2 holds true, psoriasis phase III LTE wins — BioWorld
- 12:00 PM · BioWorld12:00 PMFDA issues ITM Isotope’s ITM-11 a CRL for GEP-NETs — BioWorld
- 12:00 PM · BioWorld12:00 PMVaderis grabs $152M series B for HHT phase III — BioWorld
- 9:40 AM · BioPharma Dive9:40 AMChasing Dupixent, a biotech aims to make better antibody drugs for eczema — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMSpyre initiates SPY-772 program in hidradenitis suppurativa — BioWorld
- 9:00 AM · BioWorld9:00 AMRemedium Bio raises $10 million series A to advance platform — BioWorld
- 9:00 AM · BioWorld9:00 AMNewco news: Infinimmune takes another shot at IL-22 with $75M series A — BioWorld
- 9:00 AM · BioWorld9:00 AMFDA clears IND for Ribox’s RXIM-002 for autoimmune cytopenias — BioWorld
- 9:00 AM · BioWorld9:00 AMAcurx and Leiden University enter new antibiotic partnership — BioWorld
- 8:00 AM · BioPharma Dive8:00 AMEpicrispr lands $90M to advance epigenetic editing drug for rare muscle disease — BioPharma Dive
- 7:43 AM · BioPharma Dive7:43 AMTrump signs order seeking to upend childhood vaccine schedule — BioPharma Dive
- 6:25 AM · Pharmaceutical Technology6:25 AMBMS banks on Texas for $2.3bn multi-modal manufacturing facility — Pharmaceutical Technology
- 5:45 AM · Pharmaceutical Technology5:45 AMBeOne and Revolution Medicines partner for oncology therapies — Pharmaceutical Technology
- 4:49 AM · Pharmaceutical Technology4:49 AMJazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront — Pharmaceutical Technology
- 4:30 AM · STAT News
- 4:00 AM · Drug Discovery World4:00 AMMindMaze Therapeutics refocuses efforts on neurology — Drug Discovery World
August 10, 2026
- 8:00 PM · Nature Biotechnology8:00 PMPrime prevails in Beam dispute — Nature Biotechnology